Low-molecular-weight SHMT2 inhibitors SHIN1 and SHIN2 have been developed and shown to have anti-cancer activities against large diffuse B-cell lymphoma [68] opening the way toward experimental evaluation of SHMT2 as a drug target in PPGL. The gene discussed is SHMT2; the disease is diffuse large B-cell lymphoma.